GENOR-B (06998): Lerociclib (GB491) Included in China's National Reimbursement Drug List

Stock News2025-12-08

GENOR-B (06998) announced that lerociclib (GB491) has been included in the National Reimbursement Drug List (NRDL) for 2025, released by the National Healthcare Security Administration on December 7, 2025. This marks the first inclusion of lerociclib (GB491) in the NRDL. The updated list will take effect on January 1, 2026.

Lerociclib (GB491) is a novel, highly effective, and selective oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. It is indicated for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. It can be used in combination with an aromatase inhibitor as initial endocrine therapy or with fulvestrant for patients whose disease has progressed after prior endocrine treatment.

The company believes that the inclusion of lerociclib (GB491) in the NRDL will significantly improve patient access to the medication, alleviate financial burdens, and accelerate its commercialization and market penetration, thereby enhancing returns on innovation.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1153292269?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 19:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1153292269","market":"hk","top_or_hot":-1,"title":"GENOR-B (06998): Lerociclib (GB491) Included in China's National Reimbursement Drug List","media":"Stock News","content":"<p>GENOR-B (06998) announced that lerociclib (GB491) has been included in the National Reimbursement Drug List (NRDL) for 2025, released by the National Healthcare Security Administration on December 7, 2025. This marks the first inclusion of lerociclib (GB491) in the NRDL. The updated list will take effect on January 1, 2026.</p>\n<p>Lerociclib (GB491) is a novel, highly effective, and selective oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. It is indicated for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. It can be used in combination with an aromatase inhibitor as initial endocrine therapy or with fulvestrant for patients whose disease has progressed after prior endocrine treatment.</p>\n<p>The company believes that the inclusion of lerociclib (GB491) in the NRDL will significantly improve patient access to the medication, alleviate financial burdens, and accelerate its commercialization and market penetration, thereby enhancing returns on innovation.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GENOR-B (06998): Lerociclib (GB491) Included in China's National Reimbursement Drug List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGENOR-B (06998): Lerociclib (GB491) Included in China's National Reimbursement Drug List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-08 19:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>GENOR-B (06998) announced that lerociclib (GB491) has been included in the National Reimbursement Drug List (NRDL) for 2025, released by the National Healthcare Security Administration on December 7, 2025. This marks the first inclusion of lerociclib (GB491) in the NRDL. The updated list will take effect on January 1, 2026.</p>\n<p>Lerociclib (GB491) is a novel, highly effective, and selective oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. It is indicated for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. It can be used in combination with an aromatase inhibitor as initial endocrine therapy or with fulvestrant for patients whose disease has progressed after prior endocrine treatment.</p>\n<p>The company believes that the inclusion of lerociclib (GB491) in the NRDL will significantly improve patient access to the medication, alleviate financial burdens, and accelerate its commercialization and market penetration, thereby enhancing returns on innovation.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"06998","symbol_name":"嘉和生物","start_time":0,"source_url":"","article_id":"1153292269","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1153292269","pubTimestamp":1765195100,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"GENOR-B (06998) announced that lerociclib (GB491) has been included in the National Reimbursement Drug List (NRDL) for 2025, released by the National Healthcare Security Administration on December 7,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"06998":"嘉和生物","BK1574":"生物医药B类股","BK1583":"高瓴概念","BK1161":"生物科技"},"translate_title":"捷诺-B（06998）：莱罗昔布（GB491）纳入中国国家报销药品目录","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06998":1},"content_text":"GENOR-B (06998) announced that lerociclib (GB491) has been included in the National Reimbursement Drug List (NRDL) for 2025, released by the National Healthcare Security Administration on December 7, 2025. This marks the first inclusion of lerociclib (GB491) in the NRDL. The updated list will take effect on January 1, 2026.\nLerociclib (GB491) is a novel, highly effective, and selective oral cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. It is indicated for adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. It can be used in combination with an aromatase inhibitor as initial endocrine therapy or with fulvestrant for patients whose disease has progressed after prior endocrine treatment.\nThe company believes that the inclusion of lerociclib (GB491) in the NRDL will significantly improve patient access to the medication, alleviate financial burdens, and accelerate its commercialization and market penetration, thereby enhancing returns on innovation.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1153292269","isCrawlerRequest":true}